Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Recursion Pharmaceuticals, Inc.

Filed: Jun 17, 2026CIK: 0001601830
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Recursion Pharmaceuticals held its 2026 annual stockholder meeting on June 17, 2026, where shareholders elected two Class II directors: Najat Khan, Ph.D. and Franziska Michor, Ph.D., to serve until 2029. This routine governance event demonstrates strong shareholder engagement and confirms the company's board composition.

Key Takeaways

Najat Khan, Ph.D. was elected as Class II director with 210,437,751 votes in favor and 27,907,256 votes withheld

Franziska Michor, Ph.D. was elected as Class II director with 208,124,737 votes in favor and 30,220,270 votes against

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 17, 2026
Item5.02
CategoryExecutive Change
CIK0001601830
Accession #rxrx-20260617
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings